Chairman of the Board
Claudio Nessi has a 20 years experience in venture capital, investing in healthcare both in Europe and the US. Claudio has been an investor and board member of some very successful life science companies including Axovan AG, Endosense SA, PregLem SA and EUSA Pharma and currently serves on the board of directors of Anaconda Biomed and Avitide Ltd.
Claudio Nessi joined NeoMed Management in 2001 before becoming a Partner in 2004, and he heads NeoMed’s operation in Switzerland. Previously, Claudio was a Venture Partner with Genevest Consulting Group SA, Geneva. He has academic research experience in molecular biology from the Max Planck Institute and the University of Connecticut, and has published articles in leading scientific journals.
Claudio Nessi holds an MBA from Erasmus University, the Netherlands, and a Ph.D. in Genetics from the University of Pavia, Italy.
Ilias (Elias) Papatheodorou
Mr. Elias Papatheodorou brings with him more than 20 years of experience with private and public biotechnology companies, as well as with The Coca-Cola Company and Philip Morris International. As Chief Business Officer of Covagen AG, he was instrumental in the closing of a CHF46 million Series B financing round and the subsequent acquisition of Covagen by Jannsen Pharmaceuticals, a J&J Company. Previously, Elias was Senior Vice President for Operations and Business Development at Medigene AG. Elias has also served for a number of years as the CEO of Novosom AG. During his tenure, the Smarticles technology entered clinical trials in the U.S.A., the company raised funds and closed licensing deals. Finally, he engineered the sale of Novosom's assets to Marina Biotech (MRNA). He received his undergraduate education at Ithaca College, NY, and his graduate education at Cornell University, NY.
Eclosion 2 & Cie SCPC, represented by Jesus Martin Garcia
Jesús Martin Garcia began his career in 1983 at the World Economic Foundation, and in 1989 joined McKinsey & Co, where he led studies in the pharmaceutical and food industries. By 1993, he chose the entrepreneurial path by creating, investing and leading start-ups in Switzerland and the United States. He was a co-founder of LeShop in 1996, which became the Swiss leader in e-commerce and was sold to Migros. In 2003, he created Eclosion, a public-private partnership for translating scientific discoveries in the field of life sciences into innovative drugs with disruptive potential. This unique structure was instrumental in the creation of GeNeuro, which has been led by Jesús since its creation in 2006. Jesús holds a bachelor's degree in industrial sciences, a Master’s in law from Geneva University and an MBA from Harvard Business School. He serves on the Board of several biotech companies and industrial and business associations.
Andera Partners, represented by Monsieur Gilles Nobécourt
Gilles Nobécourt representing Andera Partners, Director, a French citizen, born in 1957 Gilles joined Edmond de Rothschild Investment Partners (EdRIP – now Andera Partners) in 2002.
He was advisor to the French Minister for Industry and Research, then advisor to the French Prime Minister, before joining the United Nations High Commission for Refugees as Field Officer in Africa and Latin America. He then joined Rhône-Poulenc Group and Rhône-Poulenc Rorer (Aventis), where he was Vice President of Global Operations at RPR Gencell, RPR’s biotechnology division based in San Francisco, USA, then General Manager of a commercial subsidiary in Mexico until 2000. Prior to joining EdRIP (now Andera Partners), Gilles worked at Russell Reynolds Associates as a consultant to pharmaceutical and biotechnology companies. Gilles graduated from the Paris Institute for Political Sciences (Sciences Po Paris). He holds a Master’s degree in applied economics and a certificate from Stanford University’s Graduate School of Business. He is a Director of Complix, Complexa, Genkyotex, Inotrem, Gamamabs and Crescendo Biologics Ltd.
Catherine Moukheibir has over 20 years of experience in finance, including 15 years in the biotechnology industry, holding multiple leadership roles and board roles. Most recently, Catherine was a member of the Executive Board of Innate Pharma (from 2011 to 2016). Prior to joining Innate, she was CFO of Movetis, a Belgian biotech company (from 2008 to 2010), for which she led the IPO on Euronext Brussels and then the acquisition by Shire. Previously, she was Director of Capital Markets at Zeltia (from 2001 to 2007), a Spanish biopharma and consumer chemicals company, where she steered its financial strategy. Before joining Zeltia, she was Executive Director of Investment Banking at Salomon Smith Barney and Morgan Stanley. Catherine Moukheibir is currently Chair of the Board of Directors of MedDay Pharmaceuticals and is a member of the boards of Zealand and Orphazyme. She has an MBA from Yale University.
Mary Tanner is co-founder and Senior Managing Director at the consultancy firm Evolution Life Sciences Partners LLC, specializing in strategic and financial advice for companies operating in life sciences and health care. Based in New York, Mary has held various positions at world-class investment banks such as Lehman Brothers Inc, Bear Stearns & Co, and Peter J Solomon. Mary has over 25 years of experience in health-related industries andhas developed strong expertise in the pharmaceutical, biotechnology, diagnostic, medical devices, and healthcare sectors.
She is a member of the Board of Directors of Lineagen Inc, a molecular diagnostics company, and sits on the Advisory Board of the Yale School of Management , the Investment Committee for the Yale Blavatnik Fund for translational medicine and the NYCEDC LifeSciNYC Advisory Council, a New York City sponsored biotechnology initiative.
Mary received a B.A. from Harvard University. An American citizen, she is also fluent in French.
Stéphane Verdood is a founding partner of Vesalius Biocapital and has invested in more than 15 biotech companies since 2007. Prior to founding Vesalius Biocapital, Stéphane was active as a venture coach for early-stage companies. He was a founder and managing partner at Value4Growth, a specialized Life Science consulting firm, supporting start-up companies in all aspects of company formation, product strategy and fund raising. He started his career with Arthur Andersen as an information technology auditor. After having led the mergers and acquisitions division of Arthur Andersen in Belgium from 1989 to 1995, he founded and led its business consulting division in Belgium and Luxembourg and served on the European Board of Partners. Stéphane has an MBA and a degree in commercial engineering from the Catholic University of Leuven (Belgium).
Joseph McCracken, PhD
Dr. McCracken has over more than 25 years of experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. Most recently he was Global Head for Business Development & Licensing at Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for 10 years. He previously served as Director of Business Development and Representative Director of Genentech Ltd., Genentech’s wholly owned subsidiary in Japan, and has also held the positions of Vice President of Technology Licensing and Alliances at Aventis, and Vice President of Worldwide Business and Technology Development at Rhone-Poulenc Rorer S.A
Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University